Summit Therapeutics upgraded by Barclays with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for SMMT
Across the 7 sessions after earlier SMMT headlines, the stock closed higher 3 times and lower 4 times, with a median move of 1.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | SMMT | SPY |
|---|---|---|---|
| Dec 8, 2025 | Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +1.7% | -0.3% |
| Nov 18, 2025 | Wolfe Research initiated coverage on Summit Therapeutics | -0.8% | -0.8% |
| Nov 7, 2025 | Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China | -1.5% | +0.1% |
| Nov 4, 2025 | Summit Therapeutics to Present at Upcoming Investor Conferences | -4.0% | -1.2% |
| Oct 31, 2025 | Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 | +1.4% | +0.3% |
| Oct 22, 2025 | Summit Therapeutics Raises $500 Million in Private Placement | +2.2% | -0.5% |
Quantisnow market dataNASDAQ
SMMT
Summit Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for SMMT
Full SMMT profile on Quantisnow Follow SMMT and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time